Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
Piper Sandler softens view on Cronos Group in premarket analyst action
11:08am, Tuesday, 14'th Apr 2020
Axsome Therapeutics (NASDAQ:AXSM) initiated with an Outperform rating and a $95 (58% upside) price target at Cowen and Company.Bellerophon Therapeutics (NASDAQ:BLPH) initiated with a Buy rating at Bro
Axsome Therapeutics initiated with an Outperform at Cowen AXSM
10:52am, Tuesday, 14'th Apr 2020
Axsome Therapeutics initiated with an Outperform at Cowen Cowen AXSM
The Week Ahead In Biotech: Urogen FDA Decision, Amarin, J&J Earnings And More COVID-19 Updates
05:44pm, Sunday, 12'th Apr 2020
Biotech stocks moved higher last week along with the broader market. The week witnessed a few clinical readouts and pre-announcements that reflected the coronavirus (COVID-19) impact.
Billionaires Are Gobbling Up These 3 Healthcare Stocks
08:13pm, Saturday, 11'th Apr 2020
These three developmental-stage pharma stocks are attracting some of the smartest investors right now.
Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More
01:12pm, Friday, 10'th Apr 2020
The COVID-19 pandemic has stopped enrollment in many clinical trials and postponed the start of others but there is still life in the life sciences
Axsome's AXS-07 Meets Co-Primary Goals in Migraine Study
04:37pm, Tuesday, 07'th Apr 2020
Axsome's (AXSM) AXS-07 achieves both regulatory co-primary endpoints in the phase III INTERCEPT study for the early treatment of migraine.
Fly Intel: Pre-market Movers CODX;AXSM;SEAS;TEN;XBIT;TSLA;SMPL;DGLY;DAL;TDY;MNLO
01:38pm, Monday, 06'th Apr 2020
Fly Intel: Pre-market Movers CODX AXSM SEAS TEN XBIT TSLA SMPL DGLY DAL TDY MNLO
H.C. Wainwright Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)
11:32am, Monday, 06'th Apr 2020
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Axsome Therapeutics (AXSM) today and set a price target of $200.00. The company's shares
H.C. Wainwright Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)
11:32am, Monday, 06'th Apr 2020
H.C. Wainwright analyst
Ram Selvaraju
reiterated a
Buy
rating on Axsome Therapeutics (
AXSM
–
Research Report
) today and set a price target of
$200.00
. The company’s shares closed last Friday at
Achieved freedom from migraine pain in 33% of AXS-07 patients versus 16% for placebo at 2 hours (co-primary endpoint, p=0.002) Prevented progression of migraine pain beyond.
2 Top Stocks That Aren't On Wall Street's Radar
11:39am, Saturday, 04'th Apr 2020
Adaptive Biotechnologies and Axsome Therapeutics are under-followed stocks with large upsides.
Analysts' Top Healthcare Picks: Seattle Genetics (SGEN), Minerva Neurosciences (NERV)
03:41pm, Friday, 03'rd Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Seattle Genetics (SGEN), Minerva Neurosciences (NERV) and
Analysts’ Top Healthcare Picks: Seattle Genetics (SGEN), Minerva Neurosciences (NERV)
03:41pm, Friday, 03'rd Apr 2020
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Seattle Genetics (
SGEN
–
Research Report
), Minerva Neurosciences (
NERV
–
Research Report
) and O
Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More
12:21pm, Friday, 03'rd Apr 2020
The coronavirus pandemic has shaken the global economy, but three life sciences venture capital firms this week announced new funds totaling nearly $3
Should You Buy These 3 Biotechs Now?
10:45am, Friday, 03'rd Apr 2020
These drug developers just released new clinical trial results.
